MX9304627A - Composiciones de amifostina cristalina y metodos para la preparacion y el uso de las mismas. - Google Patents

Composiciones de amifostina cristalina y metodos para la preparacion y el uso de las mismas.

Info

Publication number
MX9304627A
MX9304627A MX9304627A MX9304627A MX9304627A MX 9304627 A MX9304627 A MX 9304627A MX 9304627 A MX9304627 A MX 9304627A MX 9304627 A MX9304627 A MX 9304627A MX 9304627 A MX9304627 A MX 9304627A
Authority
MX
Mexico
Prior art keywords
compositions
present
crystalline
preparation
methods
Prior art date
Application number
MX9304627A
Other languages
English (en)
Inventor
Paul E Kennedy
Roger A Rajewski
John M Baldoni
Original Assignee
Us Bioscience
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26795942&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9304627(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/099,298 external-priority patent/US5424471A/en
Application filed by Us Bioscience filed Critical Us Bioscience
Publication of MX9304627A publication Critical patent/MX9304627A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
    • C07F9/165—Esters of thiophosphoric acids
    • C07F9/1651—Esters of thiophosphoric acids with hydroxyalkyl compounds with further substituents on alkyl

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Organic Insulating Materials (AREA)
  • Sub-Exchange Stations And Push- Button Telephones (AREA)

Abstract

La presente invención se refiere a una composición de amisfostina cristalina secada en vació térmicamente estable, estéril, y, opcionalmente, el (los) excipiente (s) farmacéuticamente aceptable (s). En forma típica, las composiciones cristalinas de la presente invención presentan una estabilidad mejorada en niveles de temperatura ubicados desde aproximadamente 4 grados centígrados hasta la temperatura ambiente durante un período de cuando menos 2 años de relación con las preparaciones de amifostina amorías sólidas existentes. Las composiciones reconstituidas de la presente invención son adecuadas para su administración a seres humanos como agente protector contra efectos radiológicos o químicos.
MX9304627A 1992-07-31 1993-07-30 Composiciones de amifostina cristalina y metodos para la preparacion y el uso de las mismas. MX9304627A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92292992A 1992-07-31 1992-07-31
US08/099,298 US5424471A (en) 1992-07-31 1993-07-29 Crystalline amifostine compositions and methods of the preparation and use of same

Publications (1)

Publication Number Publication Date
MX9304627A true MX9304627A (es) 1994-04-29

Family

ID=26795942

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9304627A MX9304627A (es) 1992-07-31 1993-07-30 Composiciones de amifostina cristalina y metodos para la preparacion y el uso de las mismas.

Country Status (22)

Country Link
US (1) US5591731A (es)
EP (1) EP0655917B1 (es)
JP (1) JP3503943B2 (es)
CN (2) CN1070370C (es)
AT (1) ATE261729T1 (es)
AU (1) AU681858B2 (es)
CA (1) CA2120133C (es)
CZ (1) CZ284417B6 (es)
DE (1) DE69333453T2 (es)
DK (1) DK0655917T3 (es)
ES (1) ES2215992T3 (es)
HU (1) HU227122B1 (es)
IL (1) IL106540A (es)
IS (1) IS1843B (es)
MX (1) MX9304627A (es)
NO (2) NO309636B1 (es)
NZ (1) NZ255182A (es)
PL (1) PL178463B1 (es)
PT (1) PT655917E (es)
RU (1) RU2125880C1 (es)
SG (1) SG47101A1 (es)
SK (1) SK283318B6 (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051563A (en) 1997-02-12 2000-04-18 U.S. Bioscience, Inc. Methods for the administration of amifostine and related compounds
US6573253B2 (en) 1997-02-12 2003-06-03 Medimmune Oncology Inc. Methods for the administration of amifostine and related compounds
US5994409A (en) * 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US6239119B1 (en) * 1998-04-27 2001-05-29 Medimmune Oncology, Inc. Topical administration of amifostine and related compounds
US6017922A (en) * 1998-05-18 2000-01-25 U.S. Bioscience, Inc. Thermally stable trimetrexates and processes for producing the same
US6407278B2 (en) 1998-11-16 2002-06-18 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and methods for the preparation and use of the same
US6384259B1 (en) * 1998-11-16 2002-05-07 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and dosage form
DE10043170C2 (de) * 2000-09-01 2002-10-24 Klinge Co Chem Pharm Fab Amifostin-Monohydrat und Verfahren zu seiner Herstellung
CN1148192C (zh) * 2000-10-19 2004-05-05 南京振中生物工程有限公司 细胞保护剂氨磷汀制剂及其制备方法
US7053072B2 (en) * 2001-05-11 2006-05-30 Medimmune Oncology, Inc. Methods for the administration of amifostine and related compounds
EP2316469A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
US7629333B2 (en) * 2002-03-29 2009-12-08 Medimmune, Llc Stable amorphous amifostine compositions and methods for the preparation and use of same
CN1305478C (zh) * 2004-05-12 2007-03-21 天津市资福医药科技开发有限公司 氨磷汀冻干制剂及其制备方法
ZA200707408B (en) 2005-02-16 2009-11-25 Anacor Pharmaceuticals Inc Boron-containing small molecules
WO2007047315A1 (en) * 2005-10-20 2007-04-26 Albemarle Corporation Amifostine dihydrate crystalline composition
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
JP2009526751A (ja) 2005-12-30 2009-07-23 アナコール ファーマシューティカルズ，インコーポレイテッド ホウ素含有小分子
CA2642583C (en) 2006-02-16 2016-08-23 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-inflammatory agents
WO2007123868A2 (en) * 2006-04-17 2007-11-01 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Organic thiophosphate antiretroviral agents
US9585849B2 (en) 2006-04-17 2017-03-07 The Burlington Hc Research Group, Inc. Broad spectrum antiviral and methods of use
US8815833B2 (en) * 2006-11-09 2014-08-26 Seidose, LLC Stable amifostine liquid concentrate
EP2564857B1 (en) 2008-03-06 2017-05-03 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-inflammatory agents
WO2009140309A2 (en) * 2008-05-12 2009-11-19 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
CN101412732B (zh) * 2008-09-02 2011-09-07 大连美罗药业股份有限公司 三水合3-氨基丙基胺乙基硫代磷酸高纯稳定晶体及其制备方法
CN101347412B (zh) * 2008-09-02 2011-07-27 大连美罗药业股份有限公司 三水合氨磷汀结晶冻干制剂及其制备方法
WO2010027975A1 (en) * 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
US8461336B2 (en) 2008-09-04 2013-06-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2010045503A1 (en) * 2008-10-15 2010-04-22 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agents
MX2011006334A (es) * 2008-12-17 2011-09-22 Anacor Pharmaceuticals Inc Polimorfos de (s)-3-amino-metil-7-(3-hidroxi-propoxi)-3h-benzo-[c] [1,2]-oxaborol-1-ol.
AU2010281439A1 (en) * 2009-07-28 2012-03-15 Anacor Pharmaceuticals, Inc. Trisubstituted boron-containing molecules
AP4039A (en) 2009-08-14 2017-02-28 Daitao Chen Boron-containing small molecules as antiprotozoal agents
US20110207701A1 (en) * 2009-08-19 2011-08-25 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
US20110124597A1 (en) * 2009-09-25 2011-05-26 Anacor Pharmaceuticals, Inc. Boron containing small molecules
WO2011049971A1 (en) 2009-10-20 2011-04-28 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
WO2011060199A1 (en) * 2009-11-11 2011-05-19 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
DK2501234T3 (en) * 2009-11-20 2017-12-04 Tonix Pharma Holdings Ltd METHODS AND COMPOSITIONS FOR TREATING SYMPTOMS CONNECTED WITH POSTTRAUMATIC LOAD RESPONSE USING CYCLOBENZAPRINE
US8716478B2 (en) 2010-01-27 2014-05-06 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
US8623911B2 (en) 2010-03-19 2014-01-07 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agent
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
EP2613788B1 (en) 2010-09-07 2017-06-21 Anacor Pharmaceuticals, Inc. Benzoxaborole derivatives for treating bacterial infections
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
TWI432204B (zh) * 2011-06-03 2014-04-01 Taiwan Hopax Chems Mfg Co Ltd 對抗自由基的醫藥組合物
CN102286020A (zh) * 2011-07-11 2011-12-21 大连美罗大药厂 一水合3-氨基丙基胺乙基硫代磷酸的制备方法
BR112015022095B1 (pt) 2013-03-15 2021-12-07 Tonix Pharmaceuticals, Inc Composição farmacêutica, métodos de fabricação, composição eutética e uso de composições
CA2915708C (en) * 2013-06-18 2018-02-06 Aminomedix Inc. Compositions and methods for the preparation of kidney protective agents comprising amifostine and amino acids
SG10201902203VA (en) 2014-09-18 2019-04-29 Tonix Pharma Holdings Ltd Eutectic formulations of cyclobenzaprine hydrochloride
CA2963458C (en) * 2014-10-02 2023-09-26 Cytosorbents Corporation Use of gastrointestinally administered porous enteron sorbent polymers to prevent or treat radiation induced mucositis, esophagitis, enteritis, colitis, and gastrointestinal acute radiation syndrome
US11447506B2 (en) 2016-05-09 2022-09-20 Anacor Pharmaceuticals, Inc. Crystal forms of crisaborole in free form and preparation method and use thereof
MY207073A (en) 2017-12-11 2025-01-28 Tonix Pharma Holdings Ltd Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
CN110616463B (zh) * 2018-10-30 2024-03-22 中国科学院化学研究所 一种制备有机半导体分子单晶或无定型物的方法
WO2020088479A1 (zh) * 2018-10-30 2020-05-07 中国科学院化学研究所 一种利用水溶液制备单晶或无定型物的方法
CN118267895A (zh) * 2018-10-30 2024-07-02 中国科学院化学研究所 一种制备药物或药物中间体无定型物的方法
CN110735176B (zh) * 2018-10-30 2024-03-22 中国科学院化学研究所 一种制备配位化合物单晶或无定型物的方法
CN110607551B (zh) * 2018-10-30 2024-02-20 中国科学院化学研究所 一种制备食品添加剂单晶或无定型物的方法
CN110735177B (zh) * 2018-10-30 2024-03-22 中国科学院化学研究所 一种利用溶液冻结制备单晶或无定型物的方法
CN110606868A (zh) * 2018-10-30 2019-12-24 中国科学院化学研究所 一种制备多肽或蛋白质单晶或无定型物的方法
EP3824880A1 (en) * 2019-11-25 2021-05-26 Clevexel Pharma Freeze-dried powder containing 2-[(3-aminopropyl)amino]ethanethiol and its use for preparing a thermogel
KR20240041506A (ko) * 2022-09-23 2024-04-01 주식회사 경보제약 아비박탐 나트륨 염의 안정한 일수화물 형태 및 그의 제조 방법
CN115957190A (zh) * 2023-01-09 2023-04-14 开封明仁药业有限公司 一种注射用氨磷汀及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3892824A (en) * 1968-12-16 1975-07-01 Southern Res Inst S-{107 -({107 -aminoalkylamino)alkyl dihydrogen phosphorothioates
JPS6041676B2 (ja) * 1977-09-21 1985-09-18 山之内製薬株式会社 Ｓ−２−（３−アミノプロピルアミノ）エチルジハイドロジエンホスホロチオエ−ト１水和結晶の新規製法
US4424216A (en) * 1979-07-31 1984-01-03 The Rockefeller University Method for the reduction of mucin viscosity
CA1265052A (en) * 1984-08-08 1990-01-30 Stanley J. Sarnoff Absorption enhancing agents
EP0473673A4 (en) * 1989-05-24 1995-05-17 Us Bioscience Method for protection from azt side effects and toxicity

Also Published As

Publication number Publication date
US5591731A (en) 1997-01-07
HUT70191A (en) 1995-09-28
IS1843B (is) 2003-01-30
HU227122B1 (en) 2010-07-28
SG47101A1 (en) 1998-03-20
SK283318B6 (sk) 2003-05-02
HU9500277D0 (en) 1995-03-28
CA2120133C (en) 1998-06-09
NZ255182A (en) 1996-12-20
AU681858B2 (en) 1997-09-11
HK1010692A1 (en) 1999-06-25
IL106540A (en) 2000-02-17
NO950343D0 (no) 1995-01-30
ATE261729T1 (de) 2004-04-15
SK11395A3 (en) 1995-07-11
RU2125880C1 (ru) 1999-02-10
NO20005775D0 (no) 2000-11-15
CN1070370C (zh) 2001-09-05
NO315691B1 (no) 2003-10-13
PT655917E (pt) 2004-08-31
JPH08500104A (ja) 1996-01-09
AU4796693A (en) 1994-03-03
DK0655917T3 (da) 2004-07-26
ES2215992T3 (es) 2004-10-16
CZ284417B6 (cs) 1998-11-11
NO5775A (no) 1995-03-22
DE69333453D1 (de) 2004-04-22
CA2120133A1 (en) 1994-02-17
EP0655917A1 (en) 1995-06-07
PL178463B1 (pl) 2000-05-31
CN1146428C (zh) 2004-04-21
NO950343L (no) 1995-03-22
CN1092980A (zh) 1994-10-05
DE69333453T2 (de) 2005-01-27
CZ23095A3 (en) 1995-10-18
JP3503943B2 (ja) 2004-03-08
PL307298A1 (en) 1995-05-15
EP0655917B1 (en) 2004-03-17
CN1307870A (zh) 2001-08-15
NO309636B1 (no) 2001-03-05
IL106540A0 (en) 1994-08-26
EP0655917A4 (en) 1995-08-02
IS4060A (is) 1994-02-01

Similar Documents

Publication Publication Date Title
MX9304627A (es) Composiciones de amifostina cristalina y metodos para la preparacion y el uso de las mismas.
MY110631A (en) Crystalline amifostine compositions and methods for the preparation and use of same.
ATE218580T1 (de) Cyclosporinderivate, deren herstellung und pharmazeutische zusammensetzungen
ATE218582T1 (de) Cyclosporinderivate, deren herstellung und pharmazeutische zusammensetzungen
ECSP941104A (es) Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
DE69635996D1 (de) Pharmazeutische zusammensetzungen mit hydroximsäurederivaten
PT1206189E (pt) Formulacoes para vacinas de rotavirus
IL97892A0 (en) 2,9-disubstituted-4h-pyrido(1,2-a)pyrimidin-4-ones,their preparation and pharmaceutical compositions containing them
AR010984A1 (es) Nuevos esteres de la pleuromutilina, y el acido 1-azabiciclo-4- carbanilcarbanico; procedimiento para su preparacion y composicionesfarmaceuticas que los contienen.
KR910002437A (ko) 항염증성 조성물, 항알레르기성 조성물 또는 이들 혼합성질의 조성물
IT1197516B (it) Derivati teofillinmetilanici e teofillinmetilditianici procedimento per la loro preparazione e composizioni farmaceutiche che li comprendono
DK527186D0 (da) Bronchodilaterende farmaceutisk praeparat
CY1105168T1 (el) Διφασικη συνθεση με τραμαδολη
TR199900013T2 (xx) Yeni bile�ikler.
FR2642648B1 (fr) Utilisation de derives d'alkyl-5 pyridazine comme medicaments actifs sur le systeme cholinergique
MY101266A (en) Pharmaceutical formulations
NO974651L (no) Biologisk aktive ureidoderivater som er nyttige i behandlingen av multippel sklerose
DK0490311T3 (da) Derivater af 10,11,12,13-tetrahydro-desmycosin, fremgangsmåder til fremstilling deraf og anvendelse deraf til opnåelse af farmaceutiske præparater
SE8700829L (sv) Farmaceutisk komposition
SE8504708L (sv) Nya nukleosidderivat med antiherpesegenskaper, farmaceutiska kompositioner innehallande desamma och forfarande for framstellning av de aktiva bestandsdelarna
ITMI912324A1 (it) Derivati dall'acido beta-idrossibutirrico, procedimento per la loro preparazione e relative composizioni farmaceutiche.
IT1248525B (it) Derivati dell'eseridina utili per il trattamento delle malattie associate a disordini colinergici, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.